Biogen
NEWS
We are still only in January and Celgene and Sanofi have already made a combined $20B in M&A deals.
The effort was announced last week by the Henri A. Termeer Tribute Committee.
News of the buy was tucked away in the company’s fourth-quarter financial report.
The year is already off to a good start with mergers and acquisitions in the biopharma industry.
Life sciences professionals don’t have to look far for opportunity in Genetown.
All of the recent problems have caused the company’s largest shareholder to push for a sale.
Although the stock market seems to be moving up at the beginning of this year, the U.S. equities market appears more mixed, with healthcare stocks in particular appearing more volatile.
Another attempt at developing a treatment for Alzheimer’s has hit a wall.
We now turn to six MoneyShow.com contributors for their best ideas in biotechnology, a sector with both high risk and the potential for high rewards.
JOBS
IN THE PRESS